Business

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer Surgery

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer Surgery

articleShanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class AApril 9, 20265/news/announcement-on-voluntary-disclosure-of-completion-of-inclusion-of-the-first-subject-in-phase-1-clinical-trial-of-fz-p001-sodium-for-injection-for-visualization-of-malignant-lesions-during-ovarian-cancer-surgery
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer Surgery

About this update from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer Surgery The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A